A multicentre, randomised, double blind, placebo controlled phase II study of subcutaneous interferon beta-1a in the treatment of patients with active rheumatoid arthritis

Pavelka, K.; Vencovsky, J.; Stahl, H.; Rozman, B.; Genovese, M.; Aj, Kivitz; Kivitz, A.; Alvaro, J.; Nuki, G.; Furst, D. E.; Herrero-Beaumont, G.; McInnes, I. B.; Musikic, P.; van Holten, J.; Tak, P. P.

Published in

BMJ Publishing Group, Annals of the Rheumatic Diseases, 1(64), p. 64-69, 2005

DOI: 10.1136/ard.2003.020347

Tools

Export citation

Search in Google Scholar

A multicentre, randomised, double blind, placebo controlled phase II study of subcutaneous interferon beta-1a in the treatment of patients with active rheumatoid arthritis

Journal article published in 2005 by K. Pavelka, J. Vencovsky, H. Stahl, B. Rozman, M. Genovese, Kivitz Aj, A. Kivitz, J. Alvaro, G. Nuki, D. E. Furst, G. Herrero-Beaumont

, I. B. McInnes, P. Musikic, J. van Holten, P. P. Tak

This paper is made freely available by the publisher.

Full text: Download

Preprint: archiving allowed

Upload

Postprint: archiving allowed

Upload

Published version: archiving forbidden

Policy details

Data provided by

Abstract

Objective: To assess the efficacy of interferon beta (IFNß) in combination with methotrexate in treatment of patients with rheumatoid arthritis.

Published in

Links

Tools

A multicentre, randomised, double blind, placebo controlled phase II study of subcutaneous interferon beta-1a in the treatment of patients with active rheumatoid arthritis

Abstract